Physician profile
Rosalind Daninger
NPI 1902405038
$3,519.66
in general payments reported to CMS, 2019-2025
29 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,176 · 2022: $634 · 2023: $805 · 2024: $722 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,163.51 | 2021-2025 | |
| Saluda Medical Americas, INC. | $403.35 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $288.21 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $258.82 | 2021 | |
| Allergan, INC. | $220.31 | 2021 | |
| Scilex Pharmaceuticals INC. | $214.90 | 2021-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $158.92 | 2021-2025 | Belbuca |
| Eisai INC. | $132.39 | 2021 | |
| Pfizer INC. | $125.52 | 2023-2024 | |
| Spr Therapeutics, INC | $60.48 | 2023-2025 | Sprint Pns System |
| Lundbeck LLC | $45.00 | 2022-2023 | Vyepti |
| Biodelivery Sciences International, INC. | $43.67 | 2021 | |
| Bioventus LLC | $41.89 | 2021-2023 | Stimrouter Implantable Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $37.90 | 2022 | |
| Redhill Biopharma INC. | $33.09 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $32.91 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $32.84 | 2024 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $32.67 | 2021 | |
| Merz Pharmaceuticals, LLC | $23.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.05 | 2021 | |
| Impel Pharmaceuticals INC. | $22.32 | 2023 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $19.34 | 2021 | |
| Avanos Medical | $18.84 | 2022 | |
| Nalu Medical, INC. | $17.24 | 2021 | |
| Tanabe Pharma America, INC. | $15.97 | 2021 | |
| Lilly USA, LLC | $15.49 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.31 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosalind Daninger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.